Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A4 | Q9H015 | 1/20 | 0.76 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | ALPG | P10696 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12039657 | 1.00 | SLC22A4 (0.76) | SLC22A4KDM3BPOLBALPLALPG | |
| SCHEMBL745229 | 1.00 | SLC22A4 (0.76) | SLC22A4KDM3BPOLBALPLALPG | |
| SCHEMBL9985141 | 0.86 | SLC22A4 (1.00) | SLC22A4KDM3BPOLBALPLALPG | |
| SCHEMBL20925250 | 0.85 | SLC22A4 (0.72) | SLC22A4KDM3BPOLBALPLALPG | |
| SCHEMBL20925187 | 0.84 | SLC22A4 (0.70) | SLC22A4KDM3BPOLBGAAKMT2A | |
| SCHEMBL9604220 | 0.79 | SLC22A4 (0.55) | SLC22A4KDM3BPOLBGAAKMT2A | |
| SCHEMBL1867165 | 0.76 | SLC22A4 (0.51) | SLC22A4KDM3BPOLBKMT2ATDP1 | |
| SCHEMBL12800006 | 0.76 | SLC22A4 (0.51) | SLC22A4KDM3BPOLBKMT2ATDP1 | |
| SCHEMBL1867162 | 0.76 | SLC22A4 (0.51) | SLC22A4KDM3BPOLBKMT2ATDP1 | |
| SCHEMBL9604977 | 0.75 | SLC22A4 (0.51) | SLC22A4KDM3BGAAKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113960235-A | Application and method of biomarker in preparation of lung cancer detection reagent | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2022-01-21 | — | — | CN | claimed |
| CN-119490468-A | Solid forms of acanthogenesis promoting agent | 斯皮诺吉尼克斯公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | disclosed |
| CN-113234652-B | Construction method and application of engineering bacteria for efficiently synthesizing ergothioneine | 江南大学 | 2022-09-27 | — | — | CN | disclosed |
| US-20220265611-A1 | ERGOTHIONEINE, S-METHYL-ERGOTHIONEINE, AND USES THEREOF | Consorcio Centro de Investigación Biomédica en Red, M.P. (ES) | 2022-08-25 | — | — | US | disclosed |
| CN-114667346-A | EanB enzyme mutant and application thereof | 南京纽邦生物科技有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-113189214-B | Large yellow croaker proliferation and releasing molecular marker and screening method thereof | 宁波大学 | 2022-06-21 | — | — | CN | disclosed |
| EP-4004541-A1 | ERGOTHIONEINE, S-METHYL-ERGOTHIONEINE, AND USES THEREOF | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) (ES) | 2022-06-01 | — | — | EP | disclosed |
| CN-111534535-B | Method for constructing ergothioneine producing strain | 浙江华睿生物技术有限公司 | 2022-02-22 | — | — | CN | disclosed |
| EP-3110507-B1 | COMPOSITIONS AND METHODS FOR THE REDUCTION OR PREVENTION OF HEPATIC STEATOSIS | NUSIRT SCIENCES INC (US) | 2020-11-18 | — | — | EP | disclosed |
| WO-2006127987-A2 | TREATMENT OF EYE DISORDERS WITH SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-1708689-A2 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | The President and Fellows of Harvard College (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2006105403-A2 | TREATMENT OF EYE DISORDERS WITH SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006079021-A2 | USE OF SIRTUIN-ACTIVATING COMPOUNDS FOR TREATING FLUSHING AND DRUG INDUCED WEIGHT GAIN | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006076681-A2 | NOVEL COMPOSITIONS FOR PREVENTING AND TREATING NEURODEGENERATIVE AND BLOOD COAGULATION DISORDERS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060111435-A1 | Contacting cells with sirtuin activator or inhibitor; increasing or decreasing fat accumulation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-05-25 | — | — | US | disclosed |
| US-20060084085-A1 | Methods and compositions for modulating Bax-mediated apoptosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2006-04-20 | — | — | US | disclosed |
| WO-2006007411-A2 | METHODS AND COMPOSITIONS FOR MODULATING BAX-MEDIATED APOPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20050171027-A1 | Compositions for treating or preventing obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005065667-A2 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111435-A1 | Contacting cells with sirtuin activator or inhibitor; increasing or decreasing fat accumulation | FABP4, PLIN1, SIRT1 | SLC22A4 3852/4885KDM3B 609/4885POLB 3656/4885 |
| US-20220265611-A1 | ERGOTHIONEINE, S-METHYL-ERGOTHIONEINE, AND USES THEREOF | BHMT2, GNMT, BHMT | SLC22A4 157/4885KDM3B 2722/4885POLB 3203/4885 |
| US-20060084085-A1 | Methods and compositions for modulating Bax-mediated apoptosis | BAX, BCL2, CASP3 | SLC22A4 4142/4885KDM3B 2452/4885POLB 1489/4885 |
| US-20050171027-A1 | Compositions for treating or preventing obesity and insulin resistance disorders | FABP4, GPR119, SIRT1 | SLC22A4 3792/4885KDM3B 972/4885POLB 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.